Stornoway research day series: Treating to a target of NEDA

What is NEDA? Why is it important? Why should healthcare professionals be aiming for it? DrK presents his arguments in this Stornoway research day talk to healthcare professionals.

DrK discusses the aim of treating MS until there is no evidence of disease activity (NEDA). He explains NEDA as an evolving concept that is used to influence treatment strategies, as an outcome in trials and as a treatment strategy itself. He also makes a compelling case for the argument that stopping, slowing and reversing MS-related neurological deterioration is a long-term goal, and that people diagnosed with progressive forms of MS should be allowed access to treatments that aim for this. Not just people with relapsing remitting forms of the condition.

Watch DrK’s talk on our Youtube channel. Subscribe to our channel for more talks and videos.

This is one of the talks from the healthcare professionals day. The audience consisted of district nurses, physios, health visitors, GPs and many others that look after people on the island. Most had a general role, and didn’t specialise in MS, so these talks were to inform them about taking care of their people with MS.

The talk is part of a trip by the BartsMS and Glasgow teams to Stornoway, on the Isle of Lewis, in April 2018. In a change from the traditional research days held in London, BartsMS teamed up with the Glasgow neurology team to present two days of talks: one day for healthcare professionals on the island; and one day for people with MS and their families. There are no neurologists on the islands and patients have to fly to Glasgow. Yet rates of MS are some of the highest in the world. The teams wanted to help healthcare professionals to more effectively care for their people with MS, and to empower people with the disease and their families so they can self-monitor and better control their care and treatment. Read about our trip to Stornoway.

About the author


Add comment



Recent Posts

Recent Comments